Is Latisse Safe?
On December 7, 2008, the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee voted on unanimously to recommend FDA approval of Latisse for eyelash treatment. Latisse is formally known as bimatoprost solution. The condition Latisse will treat is defined as hypotrichosis, which means a reduced amount of hair. Latisse is made by Allergan, Inc., leaders in the health industry. Scott Whitcup, M.D., Executive Vice President of Research and Development for Allergan, stated, “Recently, unapproved eyelash products containing active drug ingredients have appeared on the market...LATISSE™ will offer consumers an FDA-approved product which has been extensively studied in well-controlled clinical trials, is manufactured to pharmaceutical standards, is appropriately labeled for use, and is regulated as a prescription product."
Allergan, Inc. has been in business since 1950 with headquarters in Irvine, California. The company employs over 8,500 people around the world today with a presence in more than 100 countries. Allergan discovers, develops and markets innovative products for health and well-being including Botox.